EF24 |
Catalog No.GC64496
One-Click Copy Product Info
|
EF24 is a novel synthetic curcumin analog.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 342808-40-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
EF24 is a novel synthetic curcumin analog [1]. EF24 induces apoptosis of cancer cells through a redox-dependent mechanism [2]. EF24 has anti-tumor and anti-aging effects [3-4].
In A549 cells, EF24 (0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM; 24h, 48h) inhibits the growth of NSCLC cells in vitro [5]. In K562 cells, EF24 (2μM; 24h) exhibits potent cell killing activity in leukemia cell lines [6]. In SKOV-3, EF24 (3μM; 48h) treatment attenuates ovarian cancer cell proliferation and metastasis [7].
In subcutaneous HCC tumor mice model, EF24 (20mg/kg; ip; 21d) inhibits tumor growth and induces apoptosis [8]. In C57/BL6 mice, EF24 (200μg/kg; ip; 14d) significantly inhibited the significant increase in JunB, JunC, and JunD levels in distant lung tissues after infrared irradiation [9]. In DU145 subcutaneous tumor mice model, EF24 (200μg/kg; ip; 4 weeks) treatment significantly slowed tumor growth [10].
References:
[1]. He Y, Li W, Hu G, et al. Bioactivities of EF24, a novel curcumin analog: a review. Frontiers in Oncology. 2018 Dec 11; 8: 614.
[2]. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-cancer drugs. 2005 Mar 1;16(3):263-275.
[3]. Sazdova I, Keremidarska-Markova M, Dimitrova D, et al. Anticarcinogenic potency of EF24: An overview of its pharmacokinetics, efficacy, mechanism of action, and nanoformulation for drug delivery. Cancers. 2023 Nov 20; 15(22): 5478.
[4]. Li W, He Y, Zhang R, et al. The curcumin analog EF24 is a novel senolytic agent. Aging (Albany NY). 2019 Jan 28;11(2):771.
[5]. Chang M, Shang M, Yuan F, et al. EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation. Cancer Cell International. 2021 Dec; 21: 1-3.
[6]. Singh AP, Wax N, Duncan J, et al. Genomic Discovery of EF-24 Targets Unveils Antitumorigenic Mechanisms in Leukemia Cells. bioRxiv. 2024 Oct 16: 2024-2010.
[7]. Zhang D, Wang Y, Dong L, et al. Therapeutic role of EF 24 targeting glucose transporter 1‐mediated metabolism and metastasis in ovarian cancer cells. Cancer science. 2013 Dec; 104(12): 1690-1696.
[8]. Liu H, Liang Y, Wang L, et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PloS one. 2012 Oct 31; 7(10): e48075.
[9]. Veeraraghavan J, Natarajan M, Awasthi V, et al. EF24, a novel curcumin analogue inhibits oncogenic activation induced by radiation abscopal effect in distant mice lungs. Cancer Research. 2011 Apr 15;71(8_Supplement):4203.
[10]. Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS one. 2013 Aug 7; 8(8): e71130.
| Cell experiment [1]: | |
Cell lines | A549 cells |
Preparation Method | For cell growth/viability (MTT) assays, A549 cells were seeded in standard 96-well plates with 4000 cells and allowed to grow for 24h to ensure attachment. The growth medium was then replaced with a medium that contained EF24 at the final concentration of 0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM and 16μM. |
Reaction Conditions | 0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM; 24h, 48h |
Applications | EF24 inhibits the growth of NSCLC cells in vitro. |
| Animal experiment [2]: | |
Animal models | Subcutaneous HCC tumor mice model |
Preparation Method | Approximately 2×106 Hepa1-6 cells in 200µL PBS were injected subcutaneously into each animal’s back (n = 20). EF24 was dissolved in dimethyl sulfoxide and diluted in sodium chloride. Ten days post-injection, EF24-treated mice (n = 10) were injected intraperitoneally (i.p.) with 200µL EF24 at a dose of 20mg/kg/d for 21d. Control mice (n = 10) were injected i.p. with 200µL PBS daily. On day 22, tumors were removed and weighed. |
Dosage form | 20mg/kg; ip; 21d |
Applications | EF24 inhibits tumor growth and induces apoptosis in a subcutaneous HCC tumor model. |
References: | |
| Cas No. | 342808-40-6 | SDF | |
| Formula | C19H15F2NO | M.Wt | 311.33 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.212 mL | 16.0601 mL | 32.1203 mL |
| 5 mM | 642.4 μL | 3.212 mL | 6.4241 mL |
| 10 mM | 321.2 μL | 1.606 mL | 3.212 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)